Novartis AG (NYSE:NVS) Stock Position Lessened by Seven Mile Advisory

Seven Mile Advisory reduced its stake in shares of Novartis AG (NYSE:NVS) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,587 shares of the company’s stock after selling 436 shares during the quarter. Seven Mile Advisory’s holdings in Novartis were worth $349,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Human Investing LLC acquired a new stake in shares of Novartis in the 4th quarter worth approximately $25,000. Union Bancaire Privee UBP SA bought a new stake in Novartis during the fourth quarter worth approximately $27,000. Legacy Investment Solutions LLC acquired a new stake in Novartis in the third quarter worth approximately $28,000. Kestra Investment Management LLC bought a new position in Novartis during the 4th quarter valued at $47,000. Finally, Clearstead Trust LLC acquired a new position in shares of Novartis during the 4th quarter valued at $51,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of NVS stock opened at $112.69 on Monday. The stock’s fifty day simple moving average is $107.92 and its 200-day simple moving average is $107.13. The company has a market capitalization of $230.34 billion, a price-to-earnings ratio of 19.17, a P/E/G ratio of 1.70 and a beta of 0.53. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 1-year low of $92.35 and a 1-year high of $120.92.

Novartis (NYSE:NVS) last issued its earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, sell-side analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were issued a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis’s dividend payout ratio is currently 42.69%.

Wall Street Analysts Forecast Growth

NVS has been the subject of several research reports. Morgan Stanley assumed coverage on Novartis in a research note on Wednesday, February 12th. They set an “underweight” rating for the company. Barclays reaffirmed an “underweight” rating on shares of Novartis in a research note on Monday, February 3rd. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. UBS Group restated a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a research note on Tuesday, February 4th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.